Another important concern with the validity of GWAS is the population stratification issue, as GWAS signals detected have mostly been attributed to cryptic population stratification (McClellan & King, 2010). discovery. First, the development risk is significantly lower, because repurposing candidates Lucidin would have already been through several stages of clinical development and have well-established safety and pharmacological profiles, thereby translating to lower costs and faster development times. For certain drug candidates, it may be possible to bypass preclinical trials and enter directly into phase II clinical trials if safety assessment and formulation development is already completed. Second, academic and small laboratories can play a major role the drug-discovery process, owing to the availability of drug screening libraries produced by biopharmaceutical companies. This will accelerate the time needed for a biopharma to scour through the pharmacopeia in search of suitable repurposing candidates. Once a suitable repurposing candidate is identified, the formulation and manufacturing chains in the pharmaceutical companies will be ready for large-scale production for emergency use, thereby avoiding the launching cost required for a drug. Third, combination strategies may be deployed with repurposed drugs to delay or reduce monotherapy resistance. Together, the above advantages have the potential to reduce the risks and accelerate return on investment, keeping the cost of bringing a repurposed drug to market to ~10% of the cost needed to market a new drug (Nosengo, 2016). Moreover, drug repurposing allows the use of molecules with novel antiviral properties as molecular tools to unravel the mechanism and pathogenesis of the (re)emerging virus, helping to uncover new therapeutic strategies from previously unexplored cellular pathways, even though not all identified targets may not eventually make it into clinical therapy. However, beyond the clear advantages presented by drug repurposing, this popular strategy of drug discovery is not without pitfalls. In most cases, the target patient population of a drug repurposing candidate will differ significantly from the one for which the drug has been approved for, lengthening the repurposing workflow required before the drug can undergo clinical trials. To further complicate matters, pharmaceutical companies are often prevented or disincentivised from taking over the further development and costs of clinical trials for some of the identified drugs, as they are protected by Lucidin intellectual property and/or programs. Even in cases where the agent is generically available, Lucidin the formulation, possibly even the route of administration, must be changed to generate a new product C both factors necessitate Phase I trials. For combination repurposing, regulators will require Phase I trials in which the repurposed agent will be tested in untried combinations to ensure that there are no unacceptable toxicities. Furthermore, target identification is often indirect and identified drugs may act on multiple targets, making them unusable for repurposing. Herein, we provide an overview of the common approaches and strategies used in drug repurposing. We will discuss how drug repurposing have helped to address the urgent need for antiviral drugs against COVID-19 using representative repurposing examples. Finally, we will discuss major challenges facing drug repurposing and Mouse monoclonal to KT3 Tag.KT3 tag peptide KPPTPPPEPET conjugated to KLH. KT3 Tag antibody can recognize C terminal, internal, and N terminal KT3 tagged proteins provide recommendations that could maximise the potential of drug repurposing during this unprecedented time. 2.?Drug repurposing approaches As with all drug repurposing projects, drug repurposing for COVID-19 undergoes these three steps before it can be considered for progression through the development pipeline: candidate drug identification; mechanistic evaluation of the drug effect in preclinical versions; and evaluation of applicant medications’ efficiency in stage II clinical studies (Pushpakom et al., 2019). Among these three techniques, the first step C the id of the medication for COVID-19 with a higher repurposing potential C may be the most important, as this might determine the repurposing achievement.